Context: Adrenocortical carcinoma (ACC) has a heterogeneous prognosis, and current medical therapies have limited efficacy in its advanced stages. Genome-wide multiomics studies identified molecular patterns associated with clinical outcome.
Conclusions: This study demonstrates that molecular profiling of FFPE tumor samples improves prognostication of ACC beyond clinical/histopathological parameters and identifies new potential drug targets. These findings pave the way to precision medicine in this rare disease. (J Clin Endocrinol Metab 103: [4511] [4512] [4513] [4514] [4515] [4516] [4517] [4518] [4519] [4520] [4521] [4522] [4523] 2018) A drenocortical carcinoma (ACC) is a rare tumor with a generally poor but heterogeneous prognosis [5-year survival rate ranging from 13% to 80% (1, 2) ]. Tumor stage according to the European Network for the Study of Adrenocortical Tumors (ENSAT) classification, which has now been used also by the American Joint Committee on Cancer TNM classification system (3) , is one of the most relevant prognostic factors (1) . However, ;10% of patients with metastatic disease at diagnosis are still alive after 10 years, and .20% of patients with tumor stages I to III die within the first 3 years (1). Resection (R) status of the primary tumor (4, 5) and Ki-67 index (6) represent additional prognostic factors. A recent study also proposed a combination of clinical/ histopathological parameters (i.e., tumor grade, R status, age, symptoms = GRAS score) to improve prognostication in patients with advanced ACC (7) .
Genome-wide studies have identified molecular patterns associated with clinical outcome (8, 9) . Among these, a specific gene expression pattern (i.e., high BUB1B-PINK1 levels) (8, 10) , specific copy number (CN) alteration (CNA) (9) , and CpG island methylation patterns (8, 11) have been associated with a poor prognosis. However, these studies have been performed on fresh-frozen tumor samples that are difficult to collect in routine clinical settings. Moreover, cost-intensive genome-wide technologies and complex bioinformatics workup were required, which precludes the adoption of the proposed prognostic biomarkers in clinical practice.
At present, few effective pharmacological therapies are available for ACC (12) . Mitotane (Lysodren; BristolMyers Squibb, Princeton, NJ) is the only approved drug, but an objective response is observed in only ;20% of cases, and treatment is limited by severe adverse reactions (13, 14) . Even combined therapies of mitotane and cytotoxic chemotherapies, like etoposide-doxorubicin-cisplatin (15) , streptozotocin (15) , and gemcitabine plus capecitabin (16, 17) , exhibit response rates ,25%. Although some studies provided some promising insights into potential pharmacological targets (18) (19) (20) , effective targeted therapies have not been identified yet (2, 21) .
The main aim of the current study was to identify a molecular tumor signature for a prognostic classification of patients with ACC that may be easily transferred into clinical practice. To this end, we used 117 standard formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens to investigate the prognostic power of both previously proposed or new molecular markers and potential drug targets, which we evaluated by targeted next-generation sequencing (NGS).
Patients and Methods

Study protocol
This is a single-center retrospective study designed and conducted in accordance with the Declaration of Helsinki. We followed the recommendations for tumor prognostic markers studies reported in the Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) (22) . Moreover, we searched for known drug targets using the OncoKB website (23) . The study protocol was approved by local ethics committee (#88/11), and written informed consent was obtained from all patients prior to study enrollment.
Patient cohort and clinical data
In total, 107 patients were selected for the study. Inclusion criteria were histologically confirmed diagnosis of ACC and availability of FFPE tumor specimens collected between 2002 and 2016 and corresponding blood samples. Initial clinical/ histopathological parameters and follow-up data were collected through the ENSAT registry (Table 1) .
A modified version of the GRAS classification (7) (mGRAS score) was used to merge prognostically relevant clinical/ histopathological data: tumor stage (ENSAT 1 to 2 = 0 points, 3 = 1 point, 4 = 2 points), grading (Ki-67 proliferation index 0 to 9 = 0 points, 10 to 19 = 1 point, $20 = 2 points), R status (R0 = 0 points, RX = 1 point, R1 = 2 points, R2 = 3 points), age (,50 years = 0 points, $50 years = 1 point), and symptoms due to steroid autonomous secretion or tumor mass (no = 0 points, yes = 1 point).
Progression-free survival (PFS) was the major outcome being defined as the time from tumor resection (primary surgery) to first radiological evidence of disease relapse or diseaserelated death.
Material collection and DNA isolation
The final series included 117 FFPE samples (89 primary tumors, 10 local recurrences, and 18 distant metastases). In 10 cases, tumor tissues were available from consecutive surgeries of the same patients (seven with primary + metastasis, one with primary + local recurrence, one with local recurrence + metastasis, and one with two metastases). For survival analyses, only the chronologically first sample of a patient was used (either primary tumor or local recurrence/metastasis). The tumor cell content in each FFPE slide was assessed by hematoxylin and eosin staining and reached a high fraction (median, 90%; range, 60% to 95%). DNA was isolated from tumors with the GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany) and from peripheral blood with the NucleoSpin Blood L Kit (MachereyNagel, Bethlehem, PA) according to the manufacturer's instructions. Qualitative and quantitative evaluation of DNA fragmentation was assessed by the GeneRead DNA Quanti-MIZE Assay Kit (384) (Qiagen). Quantitative PCRs were performed with a SYBRGreen mix according to the manufacturer's protocol and measured with a ViiA7 RT-PCR System (Thermo Fisher Scientific, Manassas, VA). Data were analyzed with QuantStudio RT-PCR Software (Applied Biosystems, Foster City, CA). The quality of all DNA samples was calculated with GeneRead DNA QuantiMIZE_384_DataAnalysis (Qiagen) in comparison with a control DNA included in the kit. Only DNA with a quality control (QC) score (indicator of sample damage/fragmentation) #0.04 was sequenced.
Targeted DNA sequencing
Tumor and leukocyte DNAs were enriched with the GeneRead DNAseq Human Comprehensive Cancer Panel V2 and GeneRead DNAseq Panel PCR Kit V2 (both Qiagen), according to the manufacturer's protocol. This panel includes coding regions of 160 genes (7951 amplicons and 744,835 bases of target regions), many of them known or suspected to be involved in adrenocortical tumorigenesis or known drug targets. NGS was performed on a NextSeq500 with NextSeq Mid Output Reagent Kit V2 and 150-bp paired end reads (Illumina, San Diego, CA). Raw data were aligned and analyzed with GensearchNGS (Phenosystems S.A., Wallonia, Belgium). For detection of somatic point mutations and small insertions and deletions (small indels) in tumor samples, the called variants were filtered as followed: coverage .100, exon distance ,21, frequency of appearance .0.1, minor allele frequency ,0.02, and variant balance .0. Variants found also in the matched blood samples were excluded. Intronic and synonymous variants have been considered for calculating tumor mutational burden (TMB) but not for further analysis, except of those with a predicted influence on splice sites.
Impact on splicing for intronic and synonymous variants was analyzed with Alamut software (Interactive Biosoftware, Rouen, France) using five prediction algorithms: SpliceSiteFinder-like, MaxEntScan (24) , NNSPLICE (25) , GeneSplicer (26) , and Human Splicing Finder (27) . All other variants were evaluated for predicted pathogenicity by the Polymorphism Phenotyping v2 algorithm tool (PolyPhen-2) (28), Sorting Tolerant From Intolerant algorithm, and MutationTaster (29) . The Catalogue of Somatic Mutations in Cancer was used as a reference of cancer-related somatic variants. InterVar was used as an additional tool for the interpretation of variants (30) .
ZNRF3, which was previously reported to be involved in the pathogenesis of ACC (8, 9, 31) , was evaluated separately by direct Sanger sequencing. PCR primers for the coding region of ZNRF3, except exon 1, were designed with Primer3 (version 4.0.0) software (3, 32) . Sequencing data were generated with an ABI 3730 or an ABI 3130xl capillary sequencer under standard conditions and analyzed with Gensearch (Phenosystems S.A.).
TMB was calculated by summing all detected somatic variants and dividing this number by the size of the target region. Values are specified in variations per megabase (Mb) .
To analyze CNAs, we used a combination of two different approaches: the CNV analysis tool from GensearchNGS and an in-house pipeline. Single CN gains or losses have been identified by comparing the CN of matched tumor and blood samples. With GensearchNGS, a fold change (FC) of 1 was considered "normal." Hence, genes with all amplicons having an FC between 1.25 and 1.75 were considered as "heterozygous duplicated" and as "homozygous duplicated" with an FC .1.75. Genes were considered deleted when all amplicons showed an FC ,0.75. For the second approach, an initial quality assessment was performed using FastQC, v0.11.3 (Illumina). (34) . Local realignment around indels was executed with GATK, v3.5 (Broad Institute) (35) . For CNV, calling the number of reads of each amplicon was determined using the multiBamCov-Tool in the BEDTools suite, v2.26.0 (Eccles Institute for Human Genetics, University of Utah, Salt Lake City, UT) (36) . Only markers covered with an average of at least 200 reads in control samples in the respective panel were considered. For normalization, the reads for each amplicon were divided by the total number of reads for each sample. Log2 FC was calculated for each amplicon passing QC using the corresponding amplicon in the matched control. A gene was considered amplified or deleted if at least 80% of all markers in a tumor covering the gene were amplified or deleted at least 1.5-fold. In both approaches, CNAs were only investigated for genes covered by at least six probes. Only CN alterations detected with both approaches were considered.
Targeted DNA methylation analysis
Bisulfite pyrosequencing was used for quantitative methylation analysis of four tumor suppressor genes, PAX5, PAX6, PYCARD, and GSTP1, that have been demonstrated to play a substantial prognostic role in ACC (11) . A total of 500 ng DNA from tumor and matched blood samples was used to perform bisulfite conversion and cleanup of converted DNA with the EpiTect Fast 96 DNA Bisulfite Kit (Qiagen) according to the manufacturer's protocol. Target regions of the assays were selected to include the regions accessible with the MLPA ME002 tumor suppressor 2 probe mix (MRC-Holland, Amsterdam, Netherlands) (3). PCR and sequencing primers were designed with PyroMark Assay Design 2.0 software (Qiagen) (3). Bisulfite-treated DNA was amplified in 25-mL reactions containing 2.5 mL 103 PCR buffer with 20 mM MgCl 2 , 0.5 mL 10 mM dNTP mix, 1.0 mL (10 pmol) of each forward and reverse primer, 0.2 mL FastStart Taq DNA Polymerase (5 U/mL), 18.8 mL PCR-grade H 2 O, and 1 mL bisulfiteconverted DNA. PCR was carried out with an initial denaturation step at 95°C for 5 minutes, followed by 45 cycles at 95°C for 30 seconds, primer-specific annealing temperature (58°C for PAX5 and PYCARD, 59°C for PAX6, and 60°C for GSTP1) for 30 seconds, and elongation at 72°C for 30 seconds and a final extension step at 72°C for 7 minutes. Bisulfite pyrosequencing was performed on a PyroMark Q96 MD Pyrosequencing System with the PyroMark Gold Q96 CDT Reagents Kit (Qiagen). Pyro Q-CpG software (Biotage, Uppsala, Sweden) was used for data analysis.
Fluorescence in situ hybridization analysis
To validate CDK4 CN gains, we investigated six representative 2-mm-thick FFPE slides by Fluorescence in situ hybridization (FISH) analysis (two samples with "homozygous" CDK4 amplification, two with "heterozygous" CDK4 amplification, and two with normal CDK4 allele status at NGS). CDK4 gene amplification was visualized through hybridization of a Zytolight SPEC CDK4/CEN12 Dual Color Probe (ZytoVision GmbH, Germany) (D12Z3) according to the manufacturer's recommendation. At least 200 nonoverlapping nuclei per sample were evaluated by fluorescence microscopy (Zeiss Axioskop, Jena, Germany) using the appropriate filter sets. Only nuclei with a distinct nuclear border showing clear hybridization signals were evaluated. CDK4 gene was considered heterozygous amplified when the FISH signal ratio of CDK4/ CEN12 was between 1.0 and 2.0 or homozygous amplified when the ratio was $2.0. Ratios may nevertheless differ when gains affect whole chromosome 12.
Targeted gene expression analysis
The mRNA expression of BUB1B and PINK1 was evaluated by quantitative real-time RT-PCR only in samples with highquality RNA and cDNA (n = 38). All baseline clinical/ histopathological characteristics as well as follow-up data of this subgroup of patients did not differ from those of the entire series. RNA was isolated from tumors by miRNeasy FFPE (Qiagen). High RNA quality was tested using an Agilent 2100 Bioanalyzer (RNA integrity number .7.5). RNA was reverse transcribed by the Quantitec Reverse Transcription Kit (Qiagen). A quantitative RT-PCR for b-actin and GAPDH was performed, and only samples with a cycle threshold of ,35 were included for further analysis (n = 38). The expression of BUB1B and PINK1 was evaluated by quantitative RT-PCR using Taqman BUB1B (Hs01084828_m1) and PINK1 (Hs00260868_m1) probes with expressed b-actin (Hs9999903_m1) as reference (Applied Biosystems, Darmstadt, Germany). Each PCR reaction was done with 40 ng cDNA, and each analysis was performed in duplicate. Transcript levels were determined using the TaqMan Gene Expression Master Mix (Applied Biosystems), the CFX96 real-time thermocycler (Bio-Rad, Hercules, CA), and the Bio-Rad CFX Manager 2.0 software. Cycling conditions were 95°C for 3 minutes, followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. The ΔCT method was applied for normalization of gene expression levels to those of b-actin. The DCT(BUB1B)2DCT(PINK1) expression was then calculated (10) . Statistical analysis with different cutoff values was performed. The best cutoff value for a high BUB1B-PINK1 differential expression was 6.3, which was already previously suggested by De Reynies et al. (10) .
Statistical analysis
A Fisher exact or x 2 test was used to investigate dichotomic variables, whereas a two-sided t test (or Mann-Whitney nonparametric test) was used to compare two groups of continuous variables as appropriate. A nonparametric Kruskal-Wallis test, followed by Bonferroni post hoc test, was used for comparison among several groups for nonnormal distributed variables. Correlations and 95% CIs between different parameters were evaluated by linear regression analysis. Survival curves were obtained by Kaplan-Meier estimates, and the differences between two or more curves were assessed by the log-rank (Mantel-Cox) test. Multivariate regression analysis was performed by the Cox proportional hazard regression model to identify those factors that might independently influence survival.
To assess and compare the prognostic accurateness and performance of different markers or scores, we used two approaches: (i) We used the x 2 (log-rank) values (deviance x 2 test) to determine the goodness-of-fit statistic of the regression model, representing a surrogate of a likelihood ratio test; (ii) We calculated the sensitivity, specificity, and accuracy of different models categorizing patients with or without disease recurrence/progress within 24 months from primary surgery as affected/nonaffected. Finally, we considered the area under the receiving operating characteristic curve and 95% CI for predicted probability of disease progression within 24 months from primary surgery. Statistical analyses were made using GraphPad Prism (version 6.0; GraphPad Software, La Jolla, CA) and SPSS software (version 23; SPSS, Inc., Chicago, IL). P values ,0.05 were considered statistically significant.
Results
Targeted molecular analysis of ACC: overview
The clinical and histopathological characteristics of the 107 patients selected for the study are shown in the Table 1 (see also "Patients and Methods").
By performing targeted NGS in 117 ACC samples, we found a median TMB of 1.3/Mb (range: 0 to 22.8/Mb). Altogether, we found 237 somatic genetic variants (single nucleotide variants and small indels). The complete list of alterations and their characteristics is shown in an online repository (3). Considering the 10 cases with FFPE samples from consecutive surgical interventions, most variants in driver genes were conserved in samples obtained from the same patient (3). Thus, we considered only the first available sample from each of the 107 patients with ACC. Among them, 30 presented no mutations, 25 had one mutation, and 52 had at least two mutations (median per sample: 1; range: 0 to 14; $5 mutations in 13 cases). Overall, 215 protein-altering somatic variations were found, affecting 69 of 161 evaluated genes. Among the affected genes, 40 were mutated in at least two samples and 17 in at least three samples (frequency $2.8%) (3). The frequency of recurrent mutations previously described in ACC (8, 9, 31) and in our series is shown in Fig. 1A . The most frequently mutated genes were TP53 (22%), CTNNB1 (17%), NF1 (11%), APC (8.4%), ZNRF3 (8.4%), MEN1 (7.4%), GNAS (6.5%), and ATRX (6.5%). We also discovered novel recurrent mutations not clearly associated with ACC yet, such as in NOTCH1, CIC, KDM6A, BRCA1, and BRCA2 (all $2.8%) [ Fig. 1A and (3) ].
We then evaluated somatic CNVs in the same series. Most frequent CN gains were observed in CDK4 (43%), NOTCH1 (19%), TERT (12%), FGFR3 (12%), and MDM2 genes (7.4%) and CN losses at RB1 (5.6%), as expected (Fig. 1B) . The presence of amplifications at the CDK4 locus was confirmed by FISH analysis (see Fig. 2 ). We also found CN alterations that were not previously reported in ACC, such as gains in STK11 (31%) and GNA11 (17%) and losses in TNFRSF14 (30%), SMARCB1 (22%), FLCN (20%), and CHEK2 (13%) (Fig. 1B) .
Using our targeted sequencing approach, we identified three different CN patterns, consistent with a previous report (9) . Accordingly, we defined them as "chromosomal" when at least three large chromosomal regions were affected by amplifications or deletions, "quiet" when fewer than three regions were altered, and "noisy" when several small regions were affected [modified from Zheng et al. (9)]. An example of each CN pattern is reported in an online repository (3). Thirty-eight ACC samples were recognized to present a "chromosomal" pattern, 44 a "quiet" pattern, and 25 a "noisy" pattern.
The two most frequently affected pathways were p53/ Rb signaling (59.8%; including alterations in CDKN2A, CDK4, MDM2, RB1, and TP53) and Wnt/b-catenin pathway (33.6%, including alterations in APC, CTNNB1, MED12, MEN1, and ZNRF3). In 22 of 107 samples (20.6%), both pathways were involved. Three of these patients (2.8%) had variations in CTNNB1 and TP53. Another frequently altered pathway was the chromatin remodeling pathway (29.9%) (Fig. 1C) . In a lower percentage of cases, genetic variations in genes of the DNA repair (7.4%) or the mismatch repair (MMR) systems (4.5%) were observed (Fig. 1C) .
The methylation pattern of promoter regions of four preselected genes was also evaluated. The median percentage of methylated promoter regions in the tumor material was 11% at PAX5 (range, 1% to 98%), 22% at PAX6 (range, 2% to 97%), 17% at PYCARD (range, 1% to 94%), and 3% at GSTP1 (range, 1% to 74%). Considering all genes, the median value of mean methylation was 21% (range, 2% to 77%). Thirty-three tumors presented a promoter methylation status of "high" (31% of cases).
A high BUB1B-PINK1 differential expression is a known negative prognostic marker in ACC (10) . Thus, we evaluated BUB1B and PINK1 mRNA expression levels in a subgroup of 38 FFPE tumor specimens with good RNA quality (32.5%). The analysis of this series revealed a high BUB1B-PINK1 differential expression in 16 cases [42%, (3)].
Prognostic stratification
To evaluate the benefit of applying a molecular classification to prognosticate clinical outcome, we first investigated the prognostic effectiveness of ENSAT tumor staging classification in our series. As expected, the median PFS was shorter for patients with metastatic disease (ENSAT 4, n = 23) than for those with intermediate (ENSAT 3, n = 28) or early tumor stages (ENSAT 1 to 2, n = 58) (P , 0.0001, x 2 = 35.6; Fig. 3A) . However, using the mGRAS score (see Methods), we obtained an improved prognostic stratification by recognizing four subgroups with a different clinical outcome, from favorable prognosis (median PFS = 54 months) to poor prognosis (median PFS = 3 months) (P , 0.0001, x 2 = 49.0, Fig. 3B ).
Considering the results of the targeted molecular analysis, five events predicted a shorter PFS in univariate analysis: (i) presence of more than one mutation [P = 0.0015, hazard ratio (HR) = 2.12, 95% CI = 1.3 to 3.4], (ii) noisy CNA pattern (P = 0.0038, HR = 2.46, 95% CI = 1.3 to 4.5), (iii) presence of alterations in Wnt/b-catenin signaling alone or together with p53/Rb (P , 0.0001), (iv) "high" promoter methylation status (P = 0.0002, HR = 2.9, 95% CI = 1.7 to 5.0), and (v) high BUB1B-PINK1 differential expression (n = 38, P = 0.0037, HR = 2.56, 95% CI = 1.16 to 5.67). To investigate the applicability of a molecular prognostic classification in a clinical setting, we developed a simplified score excluding parameters that cannot be reliably and easily analyzed by targeted analysis in FFPE samples (i.e., CNA pattern and mRNA expression). At multivariate analysis including clinical/ histopathological parameters, presence of alterations at Wnt/b-catenin alone or with p53/Rb signaling and "high" promoter methylation status remained significant (P = 0.026, HR = 1.39, 95% CI = 1.04 to 1.87 and P = 0.003, HR = 2.03, 95% CI = 1.27 to 3.25, respectively). We then combined genetic items in a molecular score as follows: number of somatic mutations (0 to 1 = 0 points, .1 = 1 point), alterations in the Wnt/b-catenin and p53/Rb pathways (none = 0 points, only Wnt/b-catenin = 1 point, Wnt/b-catenin + p53/Rb = 2 points), and promoter region methylation pattern (#25% = 0 points, .25% = 1 point) (overall points 0 to 4). This allowed us to separate four groups with PFS as end point: score 0 (n = 35, median PFS = 36 months), score 1 (n = 30, median PFS = 9 months), score 2 (n = 22, median PFS = 6 months), and score 3 to 4 (n = 20, median PFS = 4 months) (P , 0.0001, x 2 = 34.4; for definition, see Fig. 3C ). By merging mGRAS and molecular score into a combined (COMBI) score, we obtained a further improvement in the progression risk stratification. In particular, we better distinguished a group of patients with a really favorable prognosis (median PFS = 54 months) and also three groups with good (median PFS = 13 months), intermediate (median PFS = 6 months), and poor (median PFS = 3 months) prognosis (P , 0.0001, x 2 = 68.6; for definition, see Fig. 3D ). When we tested the superiority of COMBI with respect to mGRAS score by discriminating patients with the best clinical outcome (at least 24 months free of disease progression), COMBI score showed a better prognostic performance, proven by superior specificity (58.6% vs 31.0%) and accuracy (83.3% vs 74.5%). Moreover, the area under the receiving operating characteristic curve was higher for COMBI than for mGRAS score (0.872, 95% CI = 0.800 to 0.943 vs 0.780, 95% CI = 0.689 to 0.871) (3) .
A heatmap sorted for prognosis including mGRAS score, molecular parameters, and COMBI score is shown in Fig. 4 .
We then decided to compare the prognostic power of mGRAS and COMBI score evaluating the disease-free survival (DFS) in those 74 patients with ACC who were successfully operated (R0). In this subgroup, only COMBI score was able to identify a category of patients with an extremely longer DFS: median DFS for COMBI 0 to 2 (n = 23) was 243 months, COMBI 3 to 4 (n = 30) was 13 months, COMBI 5 to 7 (n = 18) was 5.5 months, and COMBI 8 to 13 (n = 3) was 3 months [P , 0.0001, x 2 = 50.98; see (3)].
Prediction of response to therapy
In patients treated with adjuvant mitotane (n = 39), a low COMBI score (0 to 2) was slightly more powerful to predict a longer DFS than a low mGRAS (0 to 1) (P = 0.0001, x 2 = 21.5 vs P = 0.0058, x 2 = 12.5). However, similar results were obtained considering patients with superimposable disease stages who did not receive adjuvant mitotane (n = 49) (COMBI score: P = 0.0001, x 2 = 27.5; mGRAS: P = 0.0008, x 2 = 16.8), thus suggesting no specific relationship between molecular alterations and response to mitotane.
In patients with advanced ACC, none of the single molecular events showed a significant predictive role for response to mitotane monotherapy (n = 34), etoposidedoxorubicin-cisplatin (n = 52), gemcitabine plus capecitabine (n = 36), and/or streptozotocin (n = 44). These analyses were performed by considering both objective response to the investigated drugs and time to progression during treatment. 
Actionable molecular alterations
Having chosen an NGS panel that includes several known pharmacologically targetable genetic alterations allowed us to directly look for their presence in ACC. According to the level of evidence (OncoKB website), we found at least one alteration in a drug-targetable gene in 64 of our 107 patients. The list and specifics of 17 actionable genetic alterations are reported in Table 2 . The most interesting ones are CN gains at gene CDK4 (43% of cases) that are accessible by different CDK4/6 inhibitors already approved for other types of solid tumors. Moreover, recurrent alterations at NOTCH1, targeted by g secretase inhibitors; NF1, targeted by MEK inhibitors; or MDM2, targeted by MDM2 inhibitors, were recognized. Mutations in other known druggable genes, such as those coding for receptor tyrosine kinases (EGFR, KIT, and RET), members of the DNA repair system (ATM, BRCA1, and BRCA2), PTCH1, and TSC1/TSC2, were detected in a small percentage of samples (,3%). In two ACC samples, we identified the well-known Val600Gly activating mutation in the gene BRAF, which is found in ;50% of papillary thyroid carcinomas and is directly actioned by BRAF and/or MEK inhibitors. Finally, mutations and/or CN losses were also observed in MMR genes MLH1, MSH2, and MSH6, which are associated with response to immune checkpoint inhibitors such as PD1/PDL1 inhibitors.
Discussion
The current study represents the largest study combining targeted NGS and methylation analysis on ACC samples (n = 117) using FFPE tissue specimens that are easily obtainable during routine histopathological workup. Our results clearly demonstrate that these analyses are feasible on FFPE material. Furthermore, we propose, to our knowledge, a new combined histological, clinical, and molecular score that improves the prognostic stratification in this rare disease (COMBI score). Finally, we identify actionable molecular events in .50% of patients.
Interestingly, we could evaluate the genetic profile of consecutive tumors from 10 patients. In these cases, we found a good concordance between primary and recurrent tumors in terms of both TMB and mutated genes, similar to what is described for other cancer types (37) . Thus, we considered only the first available tumor sample for each single patient (n = 107). Overall, we confirmed the presence of frequent ACC-associated alterations (Fig. 1A) . Notably, we also detected in a smaller percentage of cases alterations previously not clearly associated with ACC (.2.5%; i.e., mutations at NOTCH1, CIC, and BRCA1/2; amplifications in STK11 and GNA11; and deletions in TNFRSF14 and SMARCB1). In terms of signaling pathways, the most frequently involved were p53/Rb and Wnt/b-catenin, as expected. In 22 samples (20.6%), we observed alterations in both signaling pathways, representing an important negative prognostic marker-a rate that was already reported in literature (8, 9) . In the group with the worst prognosis, three patients (2.8%) with alterations in CTNNB1 and TP53 were observed. Although Ragazzon et al. found alterations in CTNNB1 and TP53 mutually exclusive (38), a small number of patients in the cohort of Assié et al. (8) and Zheng et al. (9) had variants in both genes, thus also supporting our data. We also found alterations in genes involved in chromatin remodeling, as expected (8, 9, 31, 39) . More surprisingly, we also observed recurrent genetic alterations affecting members of the MMR (i.e., MLH1, MSH2, MSH6) or homologous recombination DNA repair system (i.e., ATM, BRCA1, BRCA2).
Concerning the prognostic role of molecular markers, we could confirm in our FFPE series the impact of molecular markers already proposed in studies on fresh-frozen material (8, 9, 31) . However, the investigation of the CN pattern was not easily achievable starting from targeted analysis in FFPE material. Similarly, the isolation of highquality RNA from FFPE tissue was successful in only 32.5% of samples, allowing investigation of mRNA expression in only a subset of patients. Therefore, we excluded these markers from further analysis. A simplified molecular prognostic score was then devised that includes mutational load, alterations in the p53/Rb and Wnt/ b-catenin pathway, and "high" promoter methylation status. However, importantly, only by merging molecular alterations with clinical/histopathological parameters included in mGRAS into a COMBI score did we obtain the best discrimination among patients with ACC with different prognostication. The COMBI score was particularly supportive to identify patients with an extremely favorable clinical outcome, showing the best predictive accuracy for discriminating patients without disease recurrence/progress within the first 24 months after primary surgery compared with the mGRAS score. The superiority of the COMBI score was even more evident when considering the capability to predict DFS in patients successfully operated. These findings might play a key role in clinical practice, helping to better select patients who do not need aggressive treatment, thus sparing unnecessary side effects to patients and costs for the community.
A targeted approach to molecular analysis has been recently proposed by Garinet et al. (40) , who validated targeted NGS for simultaneously calling mutations, chromosome alterations, and DNA methylation status. Such analysis might have clinical benefits but still needs to be validated in FFPE material. Considering other cancer types, genetic analysis by targeted NGS and methylation analysis by pyrosequencing have been performed in FFPE tumor specimens, obtaining good results (41) (42) (43) . Nevertheless, this kind of approach had not been tested in ACC samples until now. In general, it is now the task to prove that proposed molecular-driven scores are clinically helpful to guide clinicians in patient care. To this end, only a multicenter, prospective, and randomized trial will provide reliable answers, but the international ACC community seems to be well connected to perform such effort.
Furthermore, we intended to investigate the potential predictive role of molecular alterations for response to systemic chemotherapies. However, none of the evaluated alterations were associated with the response to any standard pharmacological therapy in ACC. This might have different explanations, including the heterogeneity of treatments usually used in this kind of patients and the complexity of the molecular background of ACC. Finally, we intended to identify potentially druggable molecular events. A similar approach has been used in a few previous studies in a small series of patients (up to 40) demonstrating the presence of potentially actionable genomic alterations in a subset of ACC (19, 20) . In our study, we concentrated on molecular events targeted by drugs already available for solid tumors (OncoKB). Based on our analysis, the most promising candidate is the gene CDK4. Specifically, CN gains at the CDK4 locus already have been reported in the literature on ACC (8, 19, 20) , but we observed them in an even higher percentage of cases (.40%). These alterations were confirmed with FISH analysis. Our findings may be clinically relevant because selective CDK4/6 inhibitors palbociclib and ribociclib have been approved by US Food and Drug Administration for the treatment of breast cancer (44) . Phase I to III studies are now ongoing with other CDK4/6 inhibitors in solid tumors (44) . Moreover, although they have not yet been tested in patients with ACC, CDK4/6 inhibitors have been shown to reduce cell viability in ACC cell lines (46, 47) .
Another promising drug target is the NOTCH1 gene, which was gained in .20% of cases in the present series and in .40% in a previous study (47) . The Notch pathway might represent an interesting target as it was reported to be activated in ACC (49) and can be actioned by different g secretase inhibitors or monoclonal antibodies (50) . For instance, the g secretase inhibitor PF-03084014 has already been tested in a phase I study in patients with advanced solid tumors (51) . The presence of CN gains at MDM2 (7% of cases) might also be considered encouraging targets as MDM2 inhibitors such as DS-3032b or RG7112 have been reported to reduce cell proliferation in MDM-amplified liposarcoma (52) . An interesting therapeutic option is also represented by targeting the BRCA-related DNA repair system (altered in .7% of cases) by PARP [poly (ADP-ribose) polymerase] inhibitors (i.e., olaparib, nirapanib, and rucaparib) (53) that are approved for treatment of BRCA-mutant ovarian cancer. Moreover, mutations in targetable genes coding for receptor tyrosine kinases (EGFR, KIT, RET), members of the mTOR pathway (TSC1/2), and BRAF were detected in rare cases. Finally, in 4.5% of cases, we observed mutations or CN losses in members of the MMR system (MSH2, MSH6, MLH1), which have been reported as predictive biomarkers for antitumor effects of checkpoint PD1/PDL1 inhibitors [i.e., pembrolizumab or novolumab (54, 55) ]. Our findings on actionable targets open up a new therapeutic avenue for subsets of patients with ACC.
In conclusion, our study demonstrates that molecular classification based on targeted genetic analysis is able to improve the prognostication of patients with ACC when combined with clinical/histopathological parameters. This approach paves the way to a personalized management of ACC, allowing better decisions about the need for adjuvant therapies and/or frequency of periodical postoperative monitoring. In addition, our targeted panel can at the same time identi druggable targets. In some cases, these results may be used to select patients for clinical trials or off-label use of specific anticancer drugs. The fact that all this is possible in readily available FFPE material is a major step toward precision medicine in this rare disease.
